EnteroMedics (ETRM) Says vBloc Institute Demonstrates Positive Clinical Success in Patients Struggling with Weight Loss
- Banks, telecoms lead Wall Street up; another Dow record
- Western Digital (WDC) Raises Q2 Outlook
- bluebird bio (BLUE) to Offer $200M of Common Stock
- Dave & Buster's Entertainment (PLAY) Tops Q3 EPS by 11c, Raises FY Revenue Guidance
- After-Hours Stock Movers 12/06: (PLAY) (ANTH) (WDC) Higher; (AVAV) (ESV) (BLUE) Lower (more...)
Get access to the best calls on Wall Street with StreetInsider.com's Ratings Insider Elite. Get your Free Trial here.
EnteroMedics Inc. (NASDAQ: ETRM) today announced clinical success at the Bariatric Center at Sky Ridge Medical Center in Colorado, a vBloc Institute partner, where several vBloc procedures have been performed to date by Frank H. Chae, MD, FACS, Chief Surgeon and Head of the Bariatric Center at Sky Ridge Medical Center. vBloc Institute partners are facilities that have integrated vBloc Therapy and vBloc Achieve into their practices.
"The weight loss observed in my vBloc patients is trending greater than reported in the vBloc ReCharge Study," said Dr. Chae. "Our patients have experienced more than 30 percent improvement in the percent total weight loss (TWL) in the first three months when compared to the ReCharge Study patients. While our observations are not a clinical trial, the positive results of these practical applications should be recognized, particularly as vBloc moves towards obtaining broad reimbursement coverage."
vBloc Therapy is approved for use in helping with weight loss in people aged 18 years and older who are obese, with a BMI of 40 to 45 kg/m2, or a BMI of 35 to 39.9 kg/m2 with a related health condition such as Type 2 diabetes, high blood pressure, high cholesterol levels or obstructive sleep apnea.
"vBloc Therapy is a revolutionary treatment option for morbidly obese patients who do not wish to undergo anatomy-altering weight-loss procedures," continued Dr. Chae. "I would expect vBloc to be the preferred choice of eligible patients when there is insurance coverage and they do not have to carry the full financial burden themselves."
vBloc Therapy works to control sensations of hunger using a pacemaker-like device that is implanted under the skin during a safe, minimally-invasive procedure that does not alter or remove any patient anatomy. This device can be adjusted to optimize patients' therapy needs. Patients feel the sensation of fullness, empowering them to eat less, control their appetite, make healthier choices and lose weight without the major lifestyle implications of traditional weight loss surgeries. vBloc Achieve is a comprehensive, personalized weight loss support program to help vBloc patients reach and maintain health goals. While vBloc Therapy addresses hunger signals and cravings, vBloc Achieve provides the coaching and emotional support necessary to help patients make positive lifestyle changes, including healthy, balanced eating and regular exercise that are essential to long-term weight loss success. vBloc can be adjusted postoperatively for a patient's lifestyle or eating patterns in order to optimize therapy when patients need it the most.
"We were pleased to see the impressive results from Dr. Chae and his team," said Dan Gladney, EnteroMedics President and Chief Executive Officer. "We are diligently working with our other vBloc Institute partners to document weight loss across all sites with vBloc Therapy and vBloc Achieve. The support of Dr. Chae and Sky Ridge represents key validation for the promise that vBloc holds as an effective, safe and lifelong therapy for morbidly obese patients. We are dedicated to securing reimbursement for vBloc Therapy, and continuing ahead with our highly targeted marketing strategies."
Studies have shown that after receiving vBloc Therapy, patients have experienced improvements in low-density lipoprotein (LDL) cholesterol levels, triglyceride levels, blood pressure and heart rate, as well as a reduction in waist circumference. Patients also reported an improvement in quality of life. Additionally, in one study, 85 percent of patients who received vBloc Therapy were able to maintain, decrease or discontinue their diabetes medications while achieving improved glycemic control after 12 months.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Anthera Pharma (ANTH) Announces Positive Data from Phase 2 BRIGHT-SC Week 48 Analysis
- Kite Pharma (KITE) Presents Data from ZUMA-1 Trial in NHL; Primary Endpoint of ORR Met
- Stemline Therapeutics (STML) Announces Presentation of SL-401 Phase 2 Data in AML;
Create E-mail Alert Related CategoriesCorporate News, FDA, Management Comments, Momentum Movers
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!